Cambridge, MA, USA and Zurich, Switzerland – 23rd January 2024. Vivtex Corporation (“Vivtex” or “the Company”), a biotech company aiming to transform the development of oral biologic therapies for major diseases, announces that it has entered a research collaboration with Astellas Pharma Inc. (“Astellas”), a global pharmaceutical company.

2024年1月23日，美国马萨诸塞州剑桥和瑞士苏黎世。Vivtex Corporation（“Vivtex”或“该公司”）是一家旨在改变重大疾病口服生物疗法发展的生物技术公司，宣布已与全球制药公司Astellas Pharma Inc.（“Astellas”）进行研究合作。

The collaboration is focused on the evaluation of Vivtex’s unique and proprietary GI-ORIS™ (“Gut on a chip” and AI) screening and formulation platform technology to support the development of novel, oral versions of a therapeutic candidate provided by Astellas. Maureen Deehan, CEO of Vivtex, commented: “We are delighted to enter this new collaboration with Astellas Pharma.

此次合作的重点是评估Vivtex独特且专有的GI-ORIS™ （“芯片上的肠道”和AI）筛选和配方平台技术，以支持Astellas提供的新型口服治疗候选药物的开发。Vivtex首席执行官莫林·迪汉（MaureenDeehan）评论道：“我们很高兴与阿斯特拉斯制药（Astellas Pharma）进行这项新的合作。

Over the past few years, Vivtex has worked productively with multiple leading pharma and biotech companies to apply its GI-ORIS™ platform to the challenge of improving drug oral bioavailability and thereby creating valuable new product opportunities and potential benefits to patients.” Vivtex scientists demonstrated the ability and potential of the GI-ORIS™ platform to expedite the development of new orally available biologic drugs in a 2020 study published in Nature Biomedical Engineering (ref.1).

在过去几年中，Vivtex与多家领先的制药和生物技术公司进行了卓有成效的合作，以应用其GI-ORIS™ 平台来应对提高药物口服生物利用度的挑战，从而为患者创造有价值的新产品机会和潜在益处。”Vivtex科学家证明了GI-ORIS的能力和潜力™ 在《自然生物医学工程》（参考文献1）上发表的2020年研究中，加速开发新的口服生物药物的平台。

The study showed how GI-ORIS™ can be applied to accurately model (with near-perfect predictability) the absorption of drug molecules in the small intestine, enabling Vivtex to develop novel oral formulations and delivery methodologies, previously not possible for biologic medicines based on the limitations of available technologies.

这项研究表明GI-ORIS是如何™ 可以应用于准确建模（具有近乎完美的可预测性）药物分子在小肠中的吸收，使Vivtex能够开发新的口服制剂和递送方法，而基于现有技术的局限性，生物药物以前不可能。

Vivtex has secured a worldwide, exclusive license from MIT for this foundational technology and its applications for the development of novel oral biologic therapies. Reference von Erlach, T., Saxton, S., Shi, Y. et al. Robotically handled whol.

Vivtex已经从麻省理工学院获得了这项基础技术及其在新型口腔生物疗法开发中的应用的全球独家许可。参考文献von Erlach，T.，Saxton，S.，Shi，Y.等人，机器人处理了whol。